Comparison of FLIPI, FLIPI-2, and m7-FLIPI
| Index . | Prognostic impact . | Reference . | |||||
|---|---|---|---|---|---|---|---|
| Risk group . | No. of factors . | OS . | % . | FFS . | % . | ||
| FLIPI | Low | 0-1 | 5 y | 91 | 7 | ||
| 10 y | 71 | ||||||
| Intermediate | 3-5 | 5 y | 78 | ||||
| 10 y | 51 | ||||||
| High | 2 | 5 y | 53 | ||||
| 10 y | 36 | ||||||
| FLIPI 2 | Low | 0 | 3 y | 91 | 8 | ||
| 5 y | 80 | ||||||
| Intermediate | 1-2 | 3 y | 69 | ||||
| 5 y | 51 | ||||||
| High | 3-5 | 3 y | 51 | ||||
| 5 y | 19 | ||||||
| M7-FLIPI | Low | 5 y | 68-77 | 15 | |||
| High | 5 y | 22-38 | |||||
| Index . | Prognostic impact . | Reference . | |||||
|---|---|---|---|---|---|---|---|
| Risk group . | No. of factors . | OS . | % . | FFS . | % . | ||
| FLIPI | Low | 0-1 | 5 y | 91 | 7 | ||
| 10 y | 71 | ||||||
| Intermediate | 3-5 | 5 y | 78 | ||||
| 10 y | 51 | ||||||
| High | 2 | 5 y | 53 | ||||
| 10 y | 36 | ||||||
| FLIPI 2 | Low | 0 | 3 y | 91 | 8 | ||
| 5 y | 80 | ||||||
| Intermediate | 1-2 | 3 y | 69 | ||||
| 5 y | 51 | ||||||
| High | 3-5 | 3 y | 51 | ||||
| 5 y | 19 | ||||||
| M7-FLIPI | Low | 5 y | 68-77 | 15 | |||
| High | 5 y | 22-38 | |||||
FLIPI: >4 nodal sites, lactate dehydrogenase above normal, age ≥60 y, stage III to IV, Hgb <12 g/dL; FLIPI 2: lymph node mass >6 cm, age ≥60 y, bone marrow involvement, Hgb <12 g/dL, β2-microglobulin elevation; M7-FLIPI: FLIPI factors with mutational status of 7 genes: EZH2, ARID1A, MEF2B, EP300, FOX01, CREBBP, and CARD11.
Hgb, hemoglobin.